Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation Approval bolsters Strides’ portfolio for the US by adding another differentiated and niche product with limited competition Strides
- Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
- Approval bolsters Strides’ portfolio for the US by adding another differentiated and niche product with limited competition
Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Carafate® 1gm/10mL of AbbVie. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Sucralfate Oral Suspension, 1gm/10 mL has a market size of ~US$ 124Mn as per IQVIA (March 2024). The Sucralfate Oral Suspension, 1gm/10 mL will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.
The company has 260 cumulative ANDA filings (including the acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 245+ ANDAs have been approved. The company has set a target to launch ~ 60 new products over three years in the US.
